Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2024-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company Daewoong (주)대웅, covering the period from January 1, 2024, to June 30, 2024. It contains detailed company information, business descriptions, financial highlights, and management discussions. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (such as a half-year report) that contains substantive financial data is classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-14 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details the approval of a Phase 3 clinical trial for a drug (Fexuclue) by the Chinese NMPA. Since this is a specific regulatory announcement regarding business operations and clinical trial status that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2024-08-05 Korean
생산중단(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a production suspension (manufacturing suspension) of its subsidiary, Daewoong Bio, due to violations of the Pharmaceutical Affairs Act. It details the specific manufacturing lines affected, the duration of the suspension, the impact on revenue, and the company's response. This type of disclosure regarding significant operational changes or regulatory penalties is classified as a general regulatory filing (RNS) as it does not fit into specific categories like M&A, dividends, or financial reports.
2024-07-16 Korean
타인에대한채무보증결정(자회사의 주요경영사항)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증 결정). It details a financial guarantee provided by the company for its subsidiary, PT. SELATOX BIO PHARMA. This type of disclosure is a standard corporate regulatory announcement required by the Capital Markets Act in Korea. Since it does not fit into specific categories like M&A, dividends, or share repurchases, it falls under the general regulatory filing category.
2024-07-15 Korean
[기재정정]단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details a contract amendment involving a change in the counterparty for a pharmaceutical development and supply agreement. Since this is a specific regulatory disclosure of a material business contract and does not fit into the other specialized categories like M&A or financial reports, it is classified as a general regulatory filing.
2024-07-04 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the approval of a Phase 3 clinical trial (IND) for a new drug indication by the Ministry of Food and Drug Safety. Since this is a formal regulatory disclosure of a material business event that does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2024-06-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.